Circassia raises £191M in largest London biotech IPO in 19 years


Could London could be about to catch the biotech bug that has infected the U.S.? Allergy drug firm Circassia has raised £191M in an IPO on the London Stock Exchange after selling shares for 310 pence each at a market cap of £581M.

The U.K. biotech sector hopes the listing will open the way for a new wave of IPOs, as has occurred in the U.S. The last major offering in the industry in London before Circassia's was ten years ago; the latest IPO is also the largest biotech listing since at least 1995.

However, investors are wary after the dismal performance of other biotech plays.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs